drugset / Trial / NCT06132191

Expanded Access Use of Cemiplimab in Patients With Solid Tumors

NCT06132191

Expanded access Approved for marketing Regeneron Pharmaceuticals

Summary

Provide expanded access of cemiplimab in patients with solid tumors

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Background Cemiplimab Monoclonal antibody